Aaron Gerds, MD, MS, shares results from the PAC203 trial, which enrolled patients with high-risk and heavily refractory myelofibrosis.
Robert Kreitman, MD, shares results from a new study suggesting patients with hairy cell leukemia should receive rituximab concurrently with frontline cladribine.
Tibor Kovacsovics, MD, discusses CX-01, a heparin derivative that induced high response rates in older patients newly diagnosed with acute myeloid leukemia.
Paul Richardson, MD, shares results seen with isatuximab in heavily refractory myeloma, and discusses how this new agent compares with approved monoclonal antibodies.
Iman Abou Dalle, MD, describes how blocking luteinizing hormone receptors with leuprolide can improve hematopoietic recovery in patients with leukemia who have undergone intensive...
Naveen Pemmaraju, MD, discusses results from a phase I/II trial of tagraxofusp in patients with relapsed/refractory myelofibrosis, a disease with only one approved treatment option.
David Sallman, MD, discusses the initial results seen in a phase Ib trial of the anti-CD47 antibody 5F9 in patients with acute myeloid leukemia...
Dr. Diefenbach shares results from a phase Ib/II trial of polatuzumab vedotin plus obinutuzumab and lenalidomide for relapsed/refractory follicular lymphoma.
Alok Khorana, MD, shares results from the CASSINI trial, which found that treatment with rivaroxaban reduced the risk of venous thromboembolism in patients receiving...
Austin Kulasekararaj, MD, MBBS, MRCP, FRCPath, shares results from a phase III study comparing ravulizumab with eculizumab in patients with paroxysmal nocturnal hemoglobinuria.